Clinical trial

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Active, not recruiting · Phase 3 · 4 countries · Registry ID NCT07311850

Active, not recruitingPhase 3Interventional

What this study is about

This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed

SexAll

Healthy volunteersNot accepted

ConditionObesity and Overweight

Full registry criteria

Inclusion Criteria: * BMI ≥ 30 kg/m2 or BMI ≥ 27.0 kg/m2 to \<30.0 kg/m2 and presence of at least 1 of the following weight- related comorbidities: Hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) Exclusion Criteria: * Have any form of diabetes * Have a self-reported body weight change \> 5 kg (11 pounds) within 3 months prior to Screening * Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2) * History of chronic pancreatitis or presence of acute pancreatitis within the past 180 days prior to the Screening visit; or active/current, symptomatic gallbladder disease

Treatments and study arms

MET097

Drug

Once-weekly MET097 administered via subcutaneous injection

Placebo

Drug

Once-weekly placebo administered via subcutaneous injection

Primary outcomes

Percent change from baseline in body weightBaseline (Day 0) to Week 64

Study locations

169 locations were listed when this page was built. The first 40 are shown.

MHAT Botevgrad🌐 Botevgrad, Bulgaria